Limited Coverage Drugs – Sacubitril-Valsartan

Generic Name:		sacubitril-valsartan
Strength:		24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg
Form:		tablets

Special Authority Criteria	Approval Period
For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF if all of the following clinical criteria are met: Reduced left ventricular ejection fraction (LVEF) (< 40%); AND NYHA class II to III symptoms have persisted despite at least four weeks of treatment at the optimum stable doses of: an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); AND a beta blocker; AND other recommended therapies, including an aldosterone antagonist (if tolerable). Notes: Coverage of sacubitril-valsartan for the treatment of HF is available only upon application by a cardiologist or an internal medicine specialist. Sacubitril-valsartan should be administered in place of an ACEI or an ARB.	Indefinite

Special Authority Criteria

Approval Period

For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF if all of the following clinical criteria are met:

Reduced left ventricular ejection fraction (LVEF) (< 40%);

AND

NYHA class II to III symptoms have persisted despite at least four weeks of treatment at the optimum stable doses of:

an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); AND
a beta blocker; AND
other recommended therapies, including an aldosterone antagonist (if tolerable).

Notes:

Coverage of sacubitril-valsartan for the treatment of HF is available only upon application by a cardiologist or an internal medicine specialist.
Sacubitril-valsartan should be administered in place of an ACEI or an ARB.

Indefinite